Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gut Bacteria Byproduct Predicts Heart Attack

By LabMedica International staff writers
Posted on 15 May 2013
A microbial byproduct of intestinal bacteria contributes to heart disease and serves as an accurate screening tool for predicting future risks of heart attack.

A relationship has been discovered between the biochemical by product trimethylamine N-oxide (TMAO) levels and future cardiac events like heart attack, stroke, and death, even in those with no prior evidence of cardiac disease risk.

Scientists at the Cleveland Clinic (Cleveland, OH, USA) examined the relationship between fasting plasma levels of TMAO and the incidence of major adverse cardiovascular events, including death, myocardial infarction, or stroke during three years of follow-up in 4,007 patients undergoing elective coronary angiography.

The investigators used a stable-isotope-dilution assay and high-performance liquid chromatography with online electrospray ionization tandem mass spectrometry on the QTRAP 5500 mass spectrometer (AB SCIEX; Framingham, MA, USA) to quantify the TMAO, trimethylamine, choline, betaine, and their d9-isotopologues.

The scientists found that higher TMAO blood levels were associated with higher future risks of death and nonfatal heart attack or stroke over the ensuing three-year period, independent of other risk factors and blood test results. Participants who had major adverse cardiovascular events also had higher baseline levels of TMAO with a median of 5.0 μM, as compared with those who did not have cardiovascular events, whose median was 3.5 μM, which was statistically significant.


The authors concluded that intestinal microbes participate in phosphatidylcholine metabolism to form circulating and urinary TMAO. They established a correlation between high plasma levels of TMAO and an increased risk of incident major adverse cardiovascular events that is independent of traditional risk factors, even in low-risk cohorts. Stanley L. Hazen, MD, PhD, a lead author of the study, said, “These studies show that measuring blood levels of TMAO could serve as a powerful tool for predicting future cardiovascular risk, even for those without known risk factors. More studies are needed to confirm that TMAO testing, like cholesterol, triglyceride or glucose levels might help guide physicians in providing individualized nutritional recommendations for preventing cardiovascular disease.” The study was published on April 25, 2013, in the New England Medical Journal.

Related Links:
Cleveland Clinic
AB SCIEX



Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Auto Clinical Chemistry Analyzer
cobas c 703
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.